Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 May 23;14(1):810–818. doi: 10.3892/ol.2017.6232

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Lim et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 4. — Synergistic effects of delphinidin with pharmacological inhibitors of PI3K/AKT and ERK1/2 MAPK on the necrosis and apoptosis of SKOV3 cells. (A) Flow cytometric analysis of SKOV3 cells by Annexin V and propidium iodide staining. (B) The percentage of cells in the upper left quadrant indicates necrotic cells as compared with non-treated SKOV3 cells. (C) The percentage of cells in the upper right quadrant indicates late apoptotic cells as compared with non-treated SKOV3 cells. Different lowercase letters indicate the statistically significant effects of treatment (P<0.05): ^acompared with non-treated control; ^bcompared with delphinidin alone; ^ccompared with delphinidin plus LY294002; ^dcompared with delphinidin plus U0126; ^ecompared with LY294002 alone; ^fcompared with U0126 alone. PI3K, phosphoinositide-3 kinase; ERK, extracellular-regulated kinase; MAPK, mitogen-activated protein kinase; FITC, fluorescein isothiocyanate.